Tag Archives: Cartier Esham

How Industry Rates Interactions with the FDA


Kicking off day one of the BIO CEO & Investor Conference in New York City, panelists in the ‘How Industry Rates Interactions with the FDA’ session brought attendees good news – communication with the FDA has improved overall. “The improvements we have seen in increased communications between FDA and sponsors is based on a continuous dialogue that has been established over the past several years in which BIO has been at the forefront,” said Jonathan Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

SBIR Funds Speed the Delivery of Breakthrough Treatments and Cures


Today, BIO’s Executive Vice President of Emerging Companies Cartier Esham presented testimony to the U.S. House of Representatives Committee on Small Business regarding oversight of the Small Business Innovation Research and Small Business Technology Transfer Programs (SBIR/STTR). Dr. Esham emphasized that SBIR plays a critical role in supporting small biotech companies and funding their early-stage research as they navigate the “valley of death,” a critical time when the scientific concepts have shown promise but the Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,